Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. This page is about the drug she was given, at the moment it was chosen.
This page helps you decide: Ticagrelor rather than clopidogrel for her NSTEMI?
After this page you can
Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.
For Mrs. K. (NSTEMI, stent, no anticoagulant), PLATO supports ticagrelor over clopidogrel: about one primary event prevented for every 53 treated for 12 months, at the cost of about one extra major bleed not related to surgery for every 143, with the benefit holding at age 75 and over; keep her aspirin at 100 mg a day or less. Three weeks later, when atrial fibrillation brings an anticoagulant, she leaves PLATO's population and the sheet points to clopidogrel. On the one-pager it sits on page 1, in the “Which P2Y12 inhibitor?” box.